• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker

    5/29/24 5:56:11 PM ET
    $ANF
    $AVGO
    $CVNA
    $LLY
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary
    Semiconductors
    Technology
    Get the next $ANF alert in real time by email

    NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking.

    The chipmaker giant has seen an astounding 186% surge since the end of May 2023, fueled by skyrocketing demand for chips in artificial intelligence development.

    Veteran Wall Street investor Ed Yardeni recently coined “Magnificent One” to differentiate Nvidia’s extraordinary performance from the Magnificent Seven.

    To illustrate the magnitude of Nvidia's market value increase, just a year ago, the company was valued at $1 trillion. Today, it boasts a staggering $2.8 trillion valuation, making it the third-largest company in the U.S.

    Nvidia’s current value is equal to Tesla Inc. (NASDAQ:TSLA), Ely Lilly & Co. (NYSE:LLY), Broadcom Inc. (NASDAQ:AVGO), Walmart Inc. (NYSE:WMT) and Mastercard Inc. (NYSE:MA) combined.

    Read Also: When Will Nvidia Be The Most Valuable Company In The World?

    However, Nvidia's spectacular ascent is eclipsed by these seven U.S. stocks, which have more than doubled the chipmaker’s impressive returns over the last year.

    7. Vera Therapeutics, Inc. (NASDAQ:VERA): 363%

    Vera Therapeutics is a biopharmaceutical company dedicated to developing transformative treatments for serious immunological diseases. The company’s stock surged due to advancements in its clinical programs and optimistic projections for its drug candidates.

    Its 363% surge since May 30, 2023, doubled the performance of Nvidia during the same timeframe.

    6. Vertiv Holdings Co. (NYSE:VRT): 413%

    Vertiv Holdings Co. provides critical digital infrastructure and continuity solutions. The company has benefited from the increasing demand for data centers and IT infrastructure, driving robust financial performance and, consequently, a substantial increase in its stock price.

    5. MicroStrategy Incorporated (NASDAQ:MSTR): 441%

    MicroStrategy Incorporated is a business intelligence company that has gained substantial attention for its significant investments in Bitcoin (CRYPTO: BTC).

    The company’s stock performance is closely tied to Bitcoin’s price movements, and its value has soared with the cryptocurrency’s rise. The largest cryptocurrency has seen a 140% rise since the end of May 2023.

    4. Abercrombie & Fitch Co. (NYSE:ANF): 503%

    Abercrombie & Fitch is a renowned fashion retailer, known for its casual wear and lifestyle products. The stock’s impressive rise is attributed to the company's successful rebranding efforts, strong e-commerce growth and improved profitability metrics, attracting investor interest.

    3. Carvana Co. (NASDAQ:CVNA): 666%

    Carvana is an online used car retailer that has revolutionized the car buying experience by offering a fully online platform with home delivery and a seven-day return policy.

    Its stock skyrocketed as the company continued to recover from a difficult period and investors regained confidence in its unique business model and growth potential.

    2. Soleno Therapeutics, Inc. (NASDAQ:SLNO): 697%

    Soleno Therapeutics focuses on developing treatments for rare diseases, with a primary emphasis on genetic disorders such as Prader-Willi syndrome. The company’s stock has surged due to positive clinical trial results and increased optimism about its pipeline of drug candidates.

    1. MoneyLion Inc. (NYSE:ML): 790%

    MoneyLion Inc. is a digital financial platform offering a range of products, including personal loans, credit-building services, and financial advisory tools. Its significant stock surge is driven by aggressive expansion and innovation in fintech services, appealing to a broad customer base looking for accessible financial solutions.

    Photo: Shutterstock

    Don’t Miss: The average American couple has saved this much money for retirement — How do you compare?

    Get the next $ANF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANF
    $AVGO
    $CVNA
    $LLY

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Walmart Inc.
    $WMT
    2/20/2026$131.00Buy → Hold
    HSBC Securities
    Walmart Inc.
    $WMT
    2/20/2026$135.00 → $140.00Outperform
    Telsey Advisory Group
    Broadcom Inc.
    $AVGO
    2/13/2026$335.00Neutral
    DA Davidson
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Mastercard Incorporated
    $MA
    2/3/2026$610.00Neutral → Outperform
    Daiwa Securities
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    Broadcom Inc.
    $AVGO
    1/30/2026$400.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $ANF
    $AVGO
    $CVNA
    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Walmart downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Walmart from Buy to Hold and set a new price target of $131.00

    2/20/26 8:23:03 AM ET
    $WMT
    Department/Specialty Retail Stores
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on Walmart with a new price target

    Telsey Advisory Group reiterated coverage of Walmart with a rating of Outperform and set a new price target of $140.00 from $135.00 previously

    2/20/26 7:54:52 AM ET
    $WMT
    Department/Specialty Retail Stores
    Consumer Discretionary

    $ANF
    $AVGO
    $CVNA
    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director You Harry L. bought $325,129 worth of shares (1,000 units at $325.13), increasing direct ownership by 3% to 36,602 units (SEC Form 4)

    4 - Broadcom Inc. (0001730168) (Issuer)

    12/22/25 5:34:40 PM ET
    $AVGO
    Semiconductors
    Technology

    Director Enright Patrick G bought $249,985 worth of shares (5,882 units at $42.50) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    12/15/25 8:07:34 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Musk Elon bought $999,959,042 worth of shares (2,568,732 units at $389.28) (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    9/15/25 6:01:19 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $ANF
    $AVGO
    $CVNA
    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANF
    $AVGO
    $CVNA
    $LLY
    SEC Filings

    View All

    SEC Form 424B5 filed by Vertiv Holdings LLC

    424B5 - Vertiv Holdings Co (0001674101) (Filer)

    2/19/26 4:37:41 PM ET
    $VRT
    Industrial Machinery/Components
    Technology

    SEC Form S-3ASR filed by Vertiv Holdings LLC

    S-3ASR - Vertiv Holdings Co (0001674101) (Filer)

    2/19/26 4:05:59 PM ET
    $VRT
    Industrial Machinery/Components
    Technology

    Walmart Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Walmart Inc. (0000104169) (Filer)

    2/19/26 6:59:55 AM ET
    $WMT
    Department/Specialty Retail Stores
    Consumer Discretionary

    $ANF
    $AVGO
    $CVNA
    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Bartlett Daniel J sold $167,179 worth of Common (1,255 units at $133.21), decreasing direct ownership by 0.21% to 586,329 units (SEC Form 4)

    4 - Walmart Inc. (0000104169) (Issuer)

    2/19/26 6:40:27 PM ET
    $WMT
    Department/Specialty Retail Stores
    Consumer Discretionary

    EVP, Chief People Officer Dozier Eric gifted 481 shares, decreasing direct ownership by 3% to 14,455 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/19/26 4:18:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.16% to 2,966 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/18/26 4:27:23 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANF
    $AVGO
    $CVNA
    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

    Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound®Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect*INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and

    2/23/26 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 4.423 Million Tokens, and Total Crypto and Total Cash Holdings of $9.6 Billion

    Bitmine has 3,040,483 staked ETH, representing $6.0 billion at $1,958 per ETH; MAVAN staking solution on track to launch Q1 2026Bitmine now owns 3.66% of the ETH token supply, over 73% of the way to the 'Alchemy of 5%' in just 7 monthsBitmine recently closed on initial $200 million investment into Beast IndustriesBitmine Crypto + Total Cash Holdings + "Moonshots" total $9.6 billion, including 4.423 million ETH tokens, total cash of $691 million, and other crypto holdingsBitmine leads crypto treasury peers by both the velocity of raising crypto NAV per share and by the high trading liquidity of BMNR stockBitmine is the 165th most traded stock in the US, trading $0.7 billion per day (5-day avg

    2/23/26 8:30:00 AM ET
    $BMNR
    $COIN
    $MSTR
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    $ANF
    $AVGO
    $CVNA
    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    $ANF
    $AVGO
    $CVNA
    $LLY
    Financials

    Live finance-specific insights

    View All

    Walmart Raises Annual Dividend to $0.99 per Share, Marking 53rd Consecutive Year of Dividend Increases

    The Board of Directors of Walmart Inc. (NASDAQ:WMT) approved an annual cash dividend for fiscal year 2027 of $0.99 per share. This represents a 5 percent increase from the $0.94 per share paid for the last fiscal year. The fiscal year 2027 annual dividend of $0.99 per share will be paid in four quarterly installments of $0.2475 per share, according to the following record and payable dates: Record Dates Payable Dates March 20, 2026 April 6, 2026 May 8, 2026 May 26, 2026 Aug. 21, 2026 Sept. 8, 2026 Dec. 11, 2026 Jan. 4, 2027 "Dividends continue to be a part of our diversified capital returns approach. We're proud to be

    2/19/26 7:03:00 AM ET
    $WMT
    Department/Specialty Retail Stores
    Consumer Discretionary

    Walmart reports revenue growth of 5.6%, up 4.9% in constant currency (cc)

    Operating income growing faster at 10.8%, up 10.5% adjusted (cc) eCommerce sales up 24% globally GAAP EPS of $0.53; Adjusted EPS of $0.74 Company announces new $30 billion share repurchase authorization Company provides outlook for Q1 and FY27 Walmart Inc. (NASDAQ:WMT): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218203787/en/ Fourth Quarter Highlights: Revenue of $190.7 billion, up 5.6%, or 4.9% (cc) Global eCommerce sales grew 24%, led by store-fulfilled pickup & delivery and marketplace Global advertising business up 37%, including VIZIO; Walmart Connect in the U.S. up 41% Membership fee revenue gr

    2/19/26 7:02:00 AM ET
    $WMT
    Department/Specialty Retail Stores
    Consumer Discretionary

    Carvana Announces Record Fourth Quarter and Full Year 2025 Results

    Record Full Year Retail Units Sold of 596,641, up 43% YoY Record Full Year Revenue of $20.3 billion, up 49% YoY Record Full Year Net Income of $1.9 billion1, up more than $1 billion YoY Record Full Year Adjusted EBITDA of $2.2 billion, up more than $850 million YoY Expects Significant Growth in Retail Units Sold and Adjusted EBITDA2 in FY 2026 and Sequential Increase in Retail Units Sold and Adjusted EBITDA2 in Q1 Carvana (NYSE:CVNA), a leading e-commerce platform for buying and selling cars, today announced financial results for the full year and quarter ended December 31, 2025. Carvana's complete fourth quarter and fiscal year 2025 financial results and management commentary are

    2/18/26 4:05:00 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $ANF
    $AVGO
    $CVNA
    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by MoneyLion Inc.

    SC 13D/A - MONEYLION INC. (0001807846) (Subject)

    12/10/24 5:27:46 PM ET
    $ML
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care